Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.82 |
| ▸ | MMP1 | P03956 | 12/20 | 0.82 |
| ▸ | MMP9 | P14780 | 9/20 | 0.82 |
| ▸ | MMP8 | P22894 | 7/20 | 0.82 |
| ▸ | MMP14 | P50281 | 2/20 | 0.79 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.79 |
| ▸ | ADAM12 | O43184 | 1/20 | 0.79 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.79 |
| ▸ | MMP3 | P08254 | 1/20 | 0.79 |
| ▸ | MMP7 | P09237 | 1/20 | 0.79 |
| ▸ | MMP12 | P39900 | 1/20 | 0.79 |
| ▸ | MMP13 | P45452 | 1/20 | 0.79 |
| ▸ | MMP15 | P51511 | 1/20 | 0.79 |
| ▸ | MMP16 | P51512 | 1/20 | 0.79 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.79 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.79 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.79 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.79 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578096 | 1.00 | MMP2 (0.82) | MMP2MMP1MMP9MMP8MMP14 | |
| SCHEMBL6577392 | 0.91 | ECE1 (0.76) | MMP2MMP1MMP9MMP8MMP14 | |
| SCHEMBL7371076 | 0.91 | ECE1 (0.76) | MMP2MMP1MMP9MMP8MMP14 | |
| SCHEMBL13519538 | 0.91 | MMP2 (0.76) | MMP2MMP1MMP9MMP8MMP14 | |
| SCHEMBL6577835 | 0.90 | MMP1 (0.68) | MMP2MMP1MMP9MMP8MMP14 | |
| SCHEMBL6577793 | 0.90 | MMP2 (1.00) | MMP2MMP1MMP9MMP8MMP14 | |
| Ilomastat SCHEMBL8190117 | 0.88 | MMP2 (1.00) | MMP2MMP1MMP9MMP8MMP14 | |
| Ilomastat SCHEMBL35303 | 0.88 | MMP2 (1.00) | MMP2MMP1MMP9MMP8MMP14 | |
| Ilomastat SCHEMBL13575799 | 0.88 | MMP2 (1.00) | MMP2MMP1MMP9MMP8MMP14 | |
| Ilomastat SCHEMBL4293696 | 0.88 | MMP2 (1.00) | MMP2MMP1MMP9MMP8MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | claimed |
| US-20120115163-A1 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2012-05-10 | — | — | US | disclosed |
| EP-2432800-A2 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | Université Joseph Fourier (FR) | 2012-03-28 | — | — | EP | disclosed |
| US-7897591-B2 | Method of treating fatty liver disease | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2010133806-A2 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | UNIVERSITE JOSEPH FOURIER (FR) | 2010-11-25 | — | — | WO | disclosed |
| US-20090221533-A1 | METHOD OF TREATING FATTY LIVER DISEASE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2007016390-A1 | MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING FATTY LIVER DISEASE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115163-A1 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | IAPP, ANPEP, ENPEP | MMP2 710/4885MMP1 330/4885MMP9 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.